key: cord-0920995-hgvqjtfa authors: Kelso, John M title: The adverse reactions to vaccines practice parameter 10 years on -what have we learned? date: 2022-01-31 journal: Ann Allergy Asthma Immunol DOI: 10.1016/j.anai.2022.01.026 sha: 3cf73ae2fd01c594928bf677389c1a80dc4999bb doc_id: 920995 cord_uid: hgvqjtfa OBJECTIVE: To provide updated information on the evaluation and management of adverse reactions to vaccines. DATA SOURCES: PubMed / MEDLINE search since publication of a practice parameter in 2012. STUDY SELECTIONS: Original articles and guidelines on adverse reactions to vaccines, including vaccines against SARS-CoV-2 /COVID-19. RESULTS: Current guidelines conclude that patients with egg allergy are not at increased risk for reaction to egg-based influenza vaccines. Except for gelatin, most patients with allergy to vaccine constituents tolerate vaccines containing them. Most patients who have immediate reactions after receiving COVID-19 vaccines go on to receive a subsequent dose uneventfully. CONCLUSION: The risk of reactions to vaccination should be weighed against the risk of suffering a vaccine-preventable disease if the vaccine is withheld. There is no need to ask about egg allergy prior to the administration of influenza vaccines, including on screening forms. In most cases, an allergy to a vaccine constituent is not a contraindication to the vaccine containing it. Patients who have had possible anaphylactic reactions to vaccines should be evaluated by an allergist rather than simply being labeled allergic, because most can go on to receive subsequent doses. Most immediate reactions to COVID-19 vaccines are not allergic, and care should be taken to not label such reactions as anaphylactic. The role, if any, of PEG in these reactions has yet to be demonstrated. A practice parameter on adverse reactions to vaccines was published in 2009, 1 and updated in 2012. 2 While most of the information contained in the 2012 document remains current, additional progress has been made in our understanding of, and approach to, adverse events following immunization, and lessons learned based on this new data will be presented in this update. The circumstances in which allergists are asked to provide recommendations relative to vaccine allergy generally fall into 2 categories; patients who may be allergic to a vaccine constituent and are concerned about receiving a vaccine containing that constituent, or patients who have had an apparent allergic reaction after receiving a vaccine and are concerned about receiving additional doses of that or other vaccines. Our goal should be for patients to receive recommended vaccines if possible, given their enormous benefit in disease prevention. 3, 4 We must provide advice based on available evidence regarding the likelihood of a vaccine reaction in a patient allergic to a constituent, or the likelihood of a reaction to a subsequent vaccine dose in a patient who may have had an allergic reaction to a previous dose. In almost all circumstances, the data is very reassuring that the vaccines will be well-tolerated. 5, 6 Withholding vaccination in patients where there is concern about a reaction to the vaccine may seem prudent or conservative; however, not vaccinating also carries real risk. Whatever risk is posed by receiving a vaccine must be weighed against the risk of not receiving the vaccine and remaining susceptible to a vaccine-preventable disease. We can help patients with their decision about whether to receive a vaccine or not by carefully listening to, and addressing their individual concerns about the risks of vaccination. Patients receive a great deal of misinformation about vaccine risks from many sources. In many cases, studies have not demonstrated any increased risk (for example autism or infertility) and we do not believe it is possible (biologically plausible) that the vaccine could cause such harm. We must however avoid telling patients that vaccines are completely safe, but rather acknowledge that serious reactions can occur but are exceedingly rare, often in the range of 1 in 1 million, and that the same rare adverse events from vaccination often occur at a higher rate from the disease itself, which can be prevented by vaccination. An addendum to the 2012 practice parameter on adverse reactions to vaccines was devoted to the issue of administering influenza vaccines to recipients with egg allergy. 2 Most influenza vaccines are grown in eggs and contain a residual amount of egg protein measured as ovalbumin content. 7 Out of concern that this small amount of ovalbumin would trigger anaphylactic reactions in egg-allergic recipients, for many years, egg allergy was considered a contraindication to receiving influenza vaccination. However, a large number of studies have specifically evaluated the administration of egg-based influenza vaccines, both the injectable inactivated influenza vaccine (IIV) and the intranasal live attenuated influenza vaccine (LAIV), to large numbers of egg-allergic patients, including those with severe reactions to the ingestion of egg, and determined that the recipients have no increased risk of allergic or other adverse reactions. 8, 9 This is almost certainly due to a threshold affect, where the amount of ovalbumin contained in the vaccines (less than 1 mcg per dose) is simply not sufficient to provoke a reaction even in the most severely egg-allergic recipients. The overwhelming majority of egg-allergic patients are children because the allergy is almost always outgrown, i.e., egg allergy in adulthood is rare. 10 Since 2016, recommendations from the American Academy of Pediatrics have stated that no special precautions are required regarding the administration of egg-based influenza vaccines to egg-allergic children, 11 and their guidance regarding the 2021-22 influenza season states unequivocally that such precautions "constitute an unnecessary barrier to immunization" and they state further that "it is not necessary to inquire about an egg allergy before the administration of any influenza vaccine, including on screening forms." 12 The only other vaccine containing egg protein is yellow fever vaccine. Although yellow fever vaccine may contain a somewhat higher quantity of ovalbumin, 13, 14 as with influenza vaccine, the amount of ovalbumin may not be sufficient to provoke a reaction even in patients with egg allergy. The package insert for yellow fever vaccine contains a protocol for the evaluation of egg-allergic recipients. 15 It is recommended that patients with egg allergy undergo prick skin testing with the vaccine full-strength, and if the result is negative, undergo intradermal testing with the vaccine diluted 1:100. For patients with negative vaccine skin test results, it is recommended that the vaccine be administered in a single dose under observation. For patients with positive vaccine skin test results, it is recommended that the vaccine be administered in graded doses under observation (Table 1 ). Most egg-allergic patients have negative yellow fever vaccine skin test results, and receive the vaccine in a single dose uneventfully. 16, 17 Although studies have validated the safety of administering the vaccine in graded doses to those eggallergic recipients with positive vaccine skin test results, 16, 17 yellow fever vaccine has also been administered to egg-allergic children with positive yellow fever vaccine skin test results as a single dose without reaction. 18 Thus, consideration can be given to administering yellow fever vaccine to egg-allergic recipients as a single dose without prior vaccine skin testing, but with an observation period afterward. If additional studies of support the safety of this approach, as with influenza vaccine, it may not be necessary to inquire about egg allergy prior to the administration of yellow fever vaccine. This journey regarding egg allergy and influenza vaccination from contraindication to nonissue has provided some important lessons. While it was not illogical to be concerned that vaccine excipients might cause reactions in recipients allergic to those excipients, making egg allergy a contraindication to influenza vaccination without evidence turned out to be inappropriate. There were undoubtedly many patients who did not receive an annual influenza vaccination for this reason and went on to suffer the consequences of influenza disease, including death. It is essential that concerns about possible allergic reactions to vaccine constituents not be raised as barriers to vaccination without evidence that allergy to the constituent actually causes reactions in vaccine recipients. There are exceedingly rare reports of patients who have had allergic reactions to vaccines due to excipients such as neomycin, thimerosal, latex, milk and yeast. However, most of these allergies are quite rare and the overwhelming majority of patients with allergy to any of these substances tolerate vaccines containing them uneventfully, again likely due to an insufficient amount of the allergen being present in the vaccine to provoke a reaction. 2 Thus, vaccine or excipient skin testing prior to the administration of vaccines containing these excipients in patients with reported allergic reactions to them is not required, and the vaccines can be administered in the usual manner ( Figure 1 ). However, in patients who have already suffered an immediate allergic reaction to a vaccine containing one of these excipients, skin testing or serum specific IgE testing for the constituent may be warranted. The only exception to this general rule that almost all patients tolerate vaccines that contain substances to which they are allergic is gelatin. A number of vaccines contain milligram quantities of gelatin (Table 2) , and the majority of anaphylactic reactions reported to these vaccines have been determined to be due to IgE directed against the gelatin they contain. [19] [20] [21] [22] [23] In some circumstances, gelatin-free vaccine alternatives are available ( Table 2 ). Allergy to gelatin is quite rare, but patients describing possible immediate-type allergic reactions to the ingestion of gelatin, or to the receipt of gelatin-containing vaccines, should be evaluated prior to receiving such vaccines (Figure 1 ). However, once again, even a confirmed gelatin allergy does not constitute a contraindication to receiving gelatin-containing vaccines. Rather, gelatin-allergic patients should undergo skin testing with required gelatin-containing vaccines, and those with negative skin test results can receive the vaccine in a single dose under observation, while those with positive skin test results could receive the vaccine in graded doses under observation (Table 1 ). Gelatin also contains alpha-gal and patients with alpha-gal syndrome may also be at risk for reactions to gelatin-containing vaccines. 24, 25 Most immediate reactions to COVID-19 vaccines are not allergic and should not be labeled Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the coronavirus disease 2019 (COVID-19) it causes were introduced in late 2020. Although no anaphylactic reactions were reported in the clinical trials leading to their approval, shortly after their use in clinical practice, a number of reactions characterized as anaphylaxis were reported, particularly to the mRNA vaccines. 26 IgE-mediated allergic reactions require prior exposure for sensitization and almost all such reactions are due to protein allergens. Thus, the presumably allergic reactions being reported to the mRNA COVID-19 vaccines were unexpected given that no one had previously been exposed to the vaccines, and that they do not contain protein. Although some of the reactions described could meet various criteria for anaphylaxis, the majority of these reactions have subsequently proved to not be allergic in nature, and most patients have gone on to receive second doses uneventfully. [27] [28] [29] The demonstration that most reactions to the mRNA COVID-19 vaccines characterized and treated as anaphylaxis turned out not to be anaphylactic reactions also provides an important lesson. It is clear that many patients have immediate adverse events following immunization that involve both symptoms and signs, that are in fact reactions to vaccination, but are not allergic reactions to the vaccine administered. Many such reactions can be characterized as immunization stress related responses (ISRR). 30 An ISRR may include stress-induced flushing, tachycardia, palpitations and shortness of breath, a vasovagal reaction leading to lightheadedness or syncope, hyperventilation causing tingling sensations, or dissociative neurological symptoms such as weakness, abnormal movements or speech difficulties. While it is important for vaccine providers to recognize anaphylaxis and treat it promptly, it is also important to realize that ISSRs occur and should be differentiated from anaphylaxis. In ISSRs, symptoms (subjective) often predominate, without signs (objective) to support them. For example, patients may complain of pruritus or tingling without visible skin changes, tongue or throat swelling with a normal oropharyngeal exam, shortness of breath without wheezing or stridor, or lightheadedness with a normal or even elevated blood pressure. Patients who have had these immediate, but not anaphylactic reactions to a COVID vaccine can receive subsequent doses in the usual manner, but be observed for 30 minutes afterward ( Figure 2 ). Many vaccine reactions characterized as anaphylaxis do not actually meet current diagnostic criteria for the diagnosis of anaphylaxis, and many that do meet the criteria may not actually be anaphylaxis. 31, 32 The Brighton Collaboration case definition for anaphylaxis as an adverse event following immunization 33 is currently undergoing revision to avoid having cases involving having only symptoms and/or nonserious signs classified as anaphylaxis. A small number of immediate reactions to COVID-19 vaccines describe reactions that are more convincingly anaphylactic. 26 The mechanism of these reactions has yet to be elucidated. As with other vaccines, in patients who have had possible anaphylactic reactions to COVID-19 vaccines, it is appropriate to perform prick skin tests with the vaccine full-strength, and if negative intradermal tests with the vaccine diluted 1:100. 2 Negative vaccine skin test results in a patient with such a history implies that the reaction was not mast cell-mediated, or at least not IgE-mediated, and it is recommended that such patients receive the vaccine in a single dose under observation. Positive vaccine skin test results in such patients imply that the vaccine may provoke a reaction, and it is recommended that such patients receive the vaccine in graded doses under observation (Figure 2 ). 34 Another option in this circumstance would be to offer an alternative vaccine (e.g., administration of a viral vector vaccine to a patient who reacted to an mRNA vaccine), also administered under observation, although the mRNA vaccines are now generally preferred over the available adenoviral vector vaccine. 35 In particularly difficult cases, where there is hesitancy to administer a second dose, consideration can be given to measuring a COVID-19 spike protein antibody titer to assess the immune response generated to the dose already administered. 36 However, it should be noted that a particular titer has not been established as a surrogate for protection and thus the presence of anti-COVID-19 spike protein antibodies does not imply the same level or duration of protection from disease conferred by completing the initial series and appropriate boosters. 35 In evaluating possible allergic reactions to the mRNA COVID-19 vaccines, an early candidate allergen was polyethylene glycol (PEG). PEG, although not an ingredient in any non-COVID vaccine, is present in other medications such as some injectable corticosteroids and oral laxatives, as well as in some foods and cosmetics. 37, 38 There are very rare reports of patients who have had IgE-mediated reactions to PEG-containing medications. 37, 38 Although not a protein, PEGs, particularly those of higher molecular weights are large enough molecules to rarely provoke IgE responses. Prior exposure and sensitization to PEG through these other second doses uneventfully despite their apparent PEG allergy. 29 The PEG in the mRNA COVID-19 vaccines is present in the lipid nanoparticles surrounding the mRNA, and some reports have suggested that these "multivalent" PEGylated nanoparticles may be more likely to cross-link IgE antibody in a way that native PEG may not. 39 Table 1 ) or consider administration as a single dose without prior vaccine skin testing under observation. b For gelatin-containing vaccines, skin test with vaccine prick full strength and if negative intradermal diluted 1:100. If positive skin test result, administer in graded doses (see Table 1 ). Adverse reactions to vaccines Adverse reactions to vaccines practice parameter 2012 update The contribution of vaccination to global health: past, present and future Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States Vaccine allergy: A decade of experience from 2 large UK allergy centers Vaccine Allergy? Skin Testing and Challenge at a Tertiary Pediatric Hospital in Melbourne Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices Administering influenza vaccine to egg-allergic persons Administration of influenza vaccines to egg-allergic recipients: A practice parameter update 2017 Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment Committee On Infectious D. Recommendations for Prevention and Control of Influenza in Children Ovalbumin content in the yellow fever vaccine Yellow Fever Vaccination In EGG-Allergic Children Yellow fever vaccine and egg allergy Safety of yellow fever vaccine administration in confirmed egg-allergic patients Des Roches A. Single-dose yellow fever vaccination is well tolerated in egg-allergic children despite positive intradermal test to the vaccine Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines Food allergy to gelatin in children with systemic immediatetype reactions, including anaphylaxis, to vaccines IgE-mediated systemic reactions to gelatin included in the varicella vaccine The gelatin story Relationship between red meat allergy and sensitization to gelatin and galactose-α-1,3-galactose Anaphylaxis after zoster vaccine: Implicating alpha-gal allergy as a possible mechanism Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing Immunization stress-related response -Redefining immunization anxiety-related reaction as an adverse event following immunization The COVID-19 Pandemic in 2021: Avoiding Overdiagnosis of Anaphylaxis Risk While Safely Vaccinating the World Ascertainment Bias in Anaphylaxis Safety Data of COVID-19 Vaccines Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data Administration of a Second Dose of the Moderna Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial Immediate-type hypersensitivity to polyethylene glycols: a review Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgGmediated complement activation Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System Antibodies against polyethylene glycol in human blood: A literature review The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach Adverse reactions to vaccines Adverse reactions to vaccines practice parameter 2012 update The contribution of vaccination to global health: past, present and future Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States Vaccine allergy: A decade of experience from 2 large UK allergy centers Vaccine Allergy? Skin Testing and Challenge at a Tertiary Pediatric Hospital in Melbourne Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices Administering influenza vaccine to egg-allergic persons Administration of influenza vaccines to egg-allergic recipients: A practice parameter update 2017 Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment Committee On Infectious D. Recommendations for Prevention and Control of Influenza in Children Ovalbumin content in the yellow fever vaccine Yellow Fever Vaccination In EGG-Allergic Children Yellow fever vaccine and egg allergy Safety of yellow fever vaccine administration in confirmed egg-allergic patients Des Roches A. Single-dose yellow fever vaccination is well tolerated in egg-allergic children despite positive intradermal test to the vaccine Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines Food allergy to gelatin in children with systemic immediatetype reactions, including anaphylaxis, to vaccines IgE-mediated systemic reactions to gelatin included in the varicella vaccine The gelatin story Relationship between red meat allergy and sensitization to gelatin and galactose-α-1,3-galactose Anaphylaxis after zoster vaccine: Implicating alpha-gal allergy as a possible mechanism Reports of Anaphylaxis After Receipt of mRNA COVID-19 Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose Immunization stress-related response -Redefining immunization anxiety-related reaction as an adverse event following immunization The COVID-19 Pandemic in 2021: Avoiding Overdiagnosis of Anaphylaxis Risk While Safely Vaccinating the World Anaphylaxis Safety Data of COVID-19 Vaccines Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data Administration of a Second Dose of the Moderna Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial Immediate-type hypersensitivity to polyethylene glycols: a review Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System Antibodies against polyethylene glycol in human blood: A literature review The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach